Novo Nordisk
NVO
1,356 hedge funds and large institutions have $15.7B invested in Novo Nordisk in 2026 Q2 according to their latest regulatory filings, with 216 funds opening new positions, 467 increasing their positions, 460 reducing their positions, and 121 closing their positions.
79% more first-time investments, than exits
New positions opened: 216 | Existing positions closed: 121
31% more capital invested
Capital invested by funds: $12B → $15.7B (+$3.7B)
27% more funds holding in top 10
Funds holding in top 10: 11 → 14 (+3)
6% more funds holding
Funds holding: 1,279 → 1,356 (+77)
2% more repeat investments, than reductions
Existing positions increased: 467 | Existing positions reduced: 460
0.06% more ownership
Funds ownership: 7.33% → 7.39% (+0.06%)
9% less call options, than puts
Call options by funds: $2.35B | Put options by funds: $2.58B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
+$211M |
| 2 |
Goldman Sachs
New York
|
+$174M |
| 3 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$129M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$128M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$98.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$270M |
| 2 |
Two Sigma Investments
New York
|
-$269M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$131M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$89.1M |
| 5 |
Jane Street
New York
|
-$87M |
NVO Hedge Fund Activity: Q2 2026 in Review
1,356 of the 8,346 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2026, worth a combined $15.7B — up 31% from $12B a quarter earlier.
Buyers outnumbered sellers: 216 funds opened new NVO positions and 121 closed out — a net gain of 95 holders — while 467 added to existing stakes and 460 trimmed.
The largest buyer was Fred Alger Management, opening a new position worth an estimated $211M. The largest seller was Susquehanna International Group, cutting an estimated $270M.
- 1,356 institutional investors held Novo Nordisk (NVO) as of Q2 2026, up from 1,279 in Q1 2026.
- Funds reported $15.7B of Novo Nordisk stock for Q2 2026, up 31% quarter-over-quarter.
- 216 funds opened new Novo Nordisk positions in Q2 2026 and 121 closed out, a net change of +95 holders.
- The largest Novo Nordisk buyer in Q2 2026 was Fred Alger Management, an estimated $211M added.
- The largest Novo Nordisk seller in Q2 2026 was Susquehanna International Group, an estimated $270M sold.
Based on aggregated 13F filings for Q2 2026.